171 related articles for article (PubMed ID: 34555031)
1. A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Demarchi M; Coliat P; Barthelemy P; Schott R; BenAbdelghani M; Kim M; Hii JCS; Feyaerts P; Ang FRX; Derde MP; Deforce F; Petit T; Schwabe C; Wynne C; Park LS; Pivot X
PLoS One; 2021; 16(9):e0248222. PubMed ID: 34555031
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
Singh I; Patel R; Patel A; Jose V
Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
[TBL] [Abstract][Full Text] [Related]
6. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
[TBL] [Abstract][Full Text] [Related]
7. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
[TBL] [Abstract][Full Text] [Related]
8. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B; Rassam D; Liao S; Ewesuedo R
Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
[TBL] [Abstract][Full Text] [Related]
9. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants.
Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y
Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
13. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
Hanes V; Chow V; Pan Z; Markus R
Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
[TBL] [Abstract][Full Text] [Related]
17. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
Eto T; Karasuyama Y; González V; Del Campo García A
Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
[TBL] [Abstract][Full Text] [Related]
18. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Markus R; Chow V; Pan Z; Hanes V
Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
20. Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
Miguel-Lillo B; Sánchez-Vidaurre S; Pérez Díaz L; Paravisini A
Pharmacol Res Perspect; 2023 Dec; 11(6):e01139. PubMed ID: 37920875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]